GSK-3β介导Graves眼病眼眶成纤维细胞促炎因子分泌与脂肪生成
该研究探讨糖原合成酶激酶-3β(GSK-3β)在Graves眼病(GO)发病中的作用。GO眼眶组织GSK-3β表达显著高于非GO对照;抑制剂CHIR 99021可减弱IL-1β或TNF-α诱导的促炎分子产生及信号通路激活,并减少脂肪分化时的脂滴和PPARγ、C/EBPα/β表达。GSK-3β可能是GO抗炎与抗脂肪生成的潜在靶点。
要点
- GO眼眶组织中GSK-3β表达显著高于非GO对照组织。
- CHIR 99021抑制GSK-3β可减弱IL-1β或TNF-α诱导的促炎分子产生。
- CHIR 99021减少脂肪分化中的脂滴及PPARγ、C/EBPα/β表达。
核心结论
- GSK-3β在GO发病中起重要作用,抑制该激酶可减弱促炎细胞因子产生和成纤维细胞向脂肪细胞分化。
- GSK-3β可能是GO抗炎和抗脂肪生成治疗的潜在靶点。
研究设计与样本
- 研究比较GO与非GO供者眼眶组织外植体中GSK-3β基因表达,使用实时定量PCR检测。
- 使用GSK-3β抑制剂CHIR 99021处理细胞,通过RT-PCR、western blot和ELISA分析促炎分子表达。
- 通过油红O染色鉴定脂肪分化,western blot检测PPARγ和C/EBPα、β水平。
主要发现
- GO组织GSK-3β表达显著高于对照组织。
- CHIR 99021降低Y216位点磷酸化的激酶活性形式。
- IL-1β或TNF-α刺激GO和非GO成纤维细胞后IL-6、IL-8、ICAM-1、COX-1和MCP-1产生增加,加入CHIR 99021后该增加被减弱。
- CHIR 99021减弱GO细胞中IL-1β和TNF-α对Akt、PI3K、NF-κB、Erk、Jnk和p38激酶的激活。
- 脂肪分化时CHIR 99021处理的成纤维细胞脂滴及PPARγ、C/EBPα和-β表达减少,且CHIR 99021逆转脂肪生成中Wnt和β-catenin的抑制。
临床怎么用
- GSK-3β表达升高见于GO眼眶组织,可作为病理机制研究的候选分子。
- GSK-3β抑制剂在体外减弱促炎因子产生和脂肪分化,提示潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine the role of glycogen synthase kinase-3β (GSK-3β) in the pathogenesis of Graves' orbitopathy(GO). METHODS: Expression of the GSK-3β gene in whole orbital tissue explants was compared between GO and non-GO donors using quantitative real-time PCR (RT-PCR). The expression of proinflammatory molecules in the presence of the GSK-3β inhibitor CHIR 99021 was analyzed using RT-PCR, western blot, and ELISA. Adipogenic differentiation was identified using Oil Red O staining, and the levels of peroxisome proliferator activator gamma (PPARγ) and CCAAT-enhancer-binding proteins (C/EBPs) α and β were determined by western blot. RESULTS: The expression of GSK-3β was significantly higher in GO tissues than in control tissues. The addition of CHIR 99021 led to a decrease in the active form of the kinase in which the Y216 residue is phosphorylated. When GO and non-GO fibroblasts were stimulated with IL-1β or TNF-α, IL-6, IL-8, intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-1 (COX-1), and monocyte chemoattractant protein 1 (MCP-1) showed increased production, which was blunted when CHIR 99021 was added. The activation of Akt, PI3K, nuclear factor (NF)-κB, Erk, Jnk, and p38 kinase by IL-1β and TNF-α was diminished with CHIR 99021 in GO cells. A decrease in lipid droplets and expression of PPARγ and c/EBPα and -β was noted in fibroblasts treated with CHIR 99021 during adipocyte differentiation. The inhibition of Wnt and β-catenin in adipogenesis was reversed by CHIR 99021. CONCLUSIONS: GSK-3β plays a significant role in GO pathogenesis. The inhibition of the kinase attenuated the proinflammatory cytokines production and fibroblast differentiation into adipocytes. GSK-3β may be a potential target for anti-inflammatory and anti-adipogenic treatment of GO.
引用
- Lee JS, Chae MK, Kikkawa DO, et al. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy. Invest Ophthalmol Vis Sci. 2020. PMID: 32735324. doi:10.1167/iovs.61.8.51
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。